You are viewing: Europe Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The Europe Plasma Fractionation Market was valued at $8437.6 Million in 2026 and projected to reach to $11986.7 Million by 2031, representing a compound annual growth rate of 7.3%. Europe's plasma fractionation market demonstrates steady expansion driven by advanced healthcare infrastructure, robust regulatory frameworks, and high demand for immunoglobulin and clotting factor therapies.

Europe Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Plasma Fractionation Market Trends and Insights

  • Europe maintains a significant share of the global plasma fractionation market, driven by advanced healthcare infrastructure, strong regulatory frameworks, and high demand for immunoglobulin and clotting factor therapies.
  • The region's aging population and increasing prevalence of immunodeficiency disorders continue to fuel market expansion throughout the forecast period. Europe's plasma fractionation sector benefits from established plasma collection networks and sophisticated manufacturing capabilities across countries including Germany, France, and Spain.
  • Between 2026 and 2031, Europe is anticipated to experience steady growth supported by rising healthcare expenditures and improved patient access to plasma-derived therapies.
  • The region's commitment to self-sufficiency in plasma supply and stringent quality standards further strengthen market dynamics and competitive positioning..

Key Market Statistics

  • CAGR (2026-2031) 7.3% CAGR
  • Market Size, 2026 ~USD 8437.6 Million
  • Forecast, 2031 ~USD 11986.7 Million
  • Geography Europe

Europe Plasma Fractionation Market Overview

Market Leadership Position :

Europe commands a substantial share of the global plasma fractionation market, valued at $8,437.6 million in 2026. The region's advanced healthcare infrastructure and established pharmaceutical ecosystem position it as a key market for plasma-derived therapies and immunoglobulin products.

Strong Regulatory Framework :

Europe's stringent regulatory standards through the EMA and national health authorities ensure high-quality plasma fractionation products. This regulatory rigor drives innovation and maintains consumer confidence in immunoglobulin and clotting factor therapies across member states.

High Demand for Immunoglobulin Therapies :

European healthcare systems show robust demand for immunoglobulin and clotting factor treatments, driven by aging populations and increased prevalence of immunodeficiency disorders. This sustained demand supports consistent market growth across the region.

Projected Growth Trajectory :

Europe's plasma fractionation market is forecast to reach $11,986.7 million by 2031, representing a 7.3% CAGR. This growth rate reflects increasing therapeutic applications, improved patient access, and expanding treatment protocols across European healthcare systems.

Europe Plasma Fractionation Market Dynamics

  • The region's aging demographic profile and increasing prevalence of rare bleeding disorders and immunodeficiency conditions fuel market growth.
  • Strong reimbursement policies and established distribution networks across major European economies support market penetration. Looking ahead to 2031, Europe's market is expected to grow from $8,437.6 million to $11,986.7 million at a 7.3% CAGR.
  • Key growth drivers include technological advancements in plasma collection and fractionation processes, expanding clinical applications, and increased healthcare spending.
  • Germany, UK, and France remain dominant markets, while emerging opportunities exist in Central and Eastern European countries with developing healthcare infrastructure..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • Europe's plasma fractionation market is projected to grow from $8,437.6M in 2026 to $11,986.7M in 2031 at a 7.3% CAGR.
      • Europe's advanced healthcare infrastructure and regulatory frameworks support sustained demand for immunoglobulin and clotting factor products.
      • The region's aging population and rising immunodeficiency disorder prevalence drive market expansion through 2031.
      • Europe's established plasma collection networks and manufacturing capabilities reinforce competitive advantage and self-sufficiency goals.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      Europe Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Pharmaceutical Manufacturers : Plasma fractionation companies and biopharmaceutical manufacturers need detailed European market data to optimize product portfolios, identify expansion opportunities, and develop region-specific commercialization strategies for immunoglobulin and clotting factor products.
      • Healthcare Providers & Hospital Systems : European hospitals, clinics, and healthcare networks require market insights to forecast plasma product demand, optimize procurement strategies, and ensure adequate supply of immunoglobulin and clotting factor therapies for patient populations.
      • Investors & Private Equity Firms : Investment professionals evaluating opportunities in European healthcare and plasma fractionation need comprehensive market sizing, growth projections, and competitive analysis to assess portfolio companies and identify acquisition targets.
      • Regulatory & Government Bodies : European health authorities, regulatory agencies, and government health departments utilize market data for policy development, healthcare planning, and ensuring adequate plasma product availability across member states.
      • Plasma Collection & Distribution Networks : Blood banks, plasma collection centers, and distribution networks across Europe need market intelligence to optimize collection strategies, forecast demand, and align operations with regional therapeutic needs and regulatory requirements.

      Europe vs. other regions

      HowEurope compares to the other 3 regional blocs covered in this market.

      North America
      ~USD 28658.5 Million · 7.8% wtd CAGR ·
      Asia Pacific
      ~USD 8714.7 Million · 8.4% wtd CAGR ·
      Latin America
      ~USD 2826.1 Million · 6.8% wtd CAGR ·
      Middle East
      ~USD 988.6 Million · 4.4% wtd CAGR ·

      Countries within Europe - compare and drill down

      Country2025 size (native)
      GermanyUSD 3030.2 Million
      UKUSD 2174.4 Million
      FranceUSD 1786.5 Million
      ItalyUSD 1258.6 Million
      SpainUSD 1001.4 Million
      Rest Of EuropeUSD 2735.6 Million

      Country market size visualization

      Germany
      USD 3030.2 Million
      UK
      USD 2174.4 Million
      France
      USD 1786.5 Million
      Italy
      USD 1258.6 Million
      Spain
      USD 1001.4 Million
      Rest Of Europe
      USD 2735.6 Million

      Reasons to Buy this Report

      • Regional Market Segmentation : Gain detailed insights into Europe's plasma fractionation market with country-level breakdowns for Germany, UK, France, Italy, Spain, and Rest of Europe. Understand market dynamics specific to each major European economy and identify high-growth opportunities.
      • Competitive Landscape Analysis : Access comprehensive competitive intelligence on European plasma fractionation manufacturers and suppliers. Identify market leaders, emerging players, and strategic partnerships shaping the European market through 2031.
      • Regulatory & Reimbursement Insights : Understand Europe's complex regulatory environment including EMA approvals, national health authority requirements, and reimbursement policies. Navigate compliance requirements and market access strategies across different European jurisdictions.
      • Growth Driver Identification : Discover key growth catalysts specific to Europe including aging populations, rising immunodeficiency diagnoses, technological innovations, and healthcare spending trends. Align business strategies with region-specific market dynamics.
      • Strategic Planning & Forecasting : Leverage accurate 2026-2031 forecasts to inform investment decisions, product development priorities, and market entry strategies. Make data-driven decisions backed by comprehensive European market analysis and trend projections.

      Frequently asked questions

      What is the projected market size for plasma fractionation in Europe by 2031?

      Europe's plasma fractionation market is forecast to reach $11,986.7 million by 2031, growing from $8,437.6 million in 2026.

      What is the CAGR for Europe's plasma fractionation market?

      Europe's plasma fractionation market is expected to grow at a compound annual growth rate of 7.3% between 2026 and 2031.

      Which factors are driving growth in Europe's plasma fractionation market?

      Key growth drivers in Europe include an aging population, increasing immunodeficiency disorder prevalence, advanced healthcare infrastructure, and strong regulatory frameworks supporting plasma-derived therapies.

      Which European countries lead the plasma fractionation market?

      Germany, France, and Spain are among Europe's leading markets, supported by established plasma collection networks and sophisticated manufacturing capabilities.

      How does Europe's plasma fractionation market compare to global trends?

      Europe's 7.3% CAGR is slightly below the global 7.6% CAGR, reflecting the region's mature market status and established healthcare infrastructure.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status